Sep 14, 2026
Brio Rx connects patients across the United States with licensed physicians through convenient online consultations and personalized prescription care, including hair loss, hair restoration, and men's health services delivered directly to patients' homes.
United States, September 14, 2026 -- Brio Rx has announced the launch of its physician-led telehealth platform, a digital healthcare service designed to make personalized medical care more accessible and convenient for patients across the United States. Through its online platform, Brio Rx connects patients with licensed healthcare providers who evaluate their individual needs and, when appropriate, develop personalized treatment plans that can include prescription medications delivered directly to their homes.

The platform focuses on providing convenient access to care for common health concerns, including hair loss, hair restoration, men's health, and other wellness needs. By combining virtual consultations, licensed medical providers, prescription fulfillment, and ongoing support, Brio Rx aims to simplify the healthcare experience while maintaining an emphasis on clinical oversight and patient care.
The launch reflects the continued development of digital healthcare services as patients increasingly seek convenient alternatives to traditional in-person healthcare. Brio Rx is designed to reduce some of the common barriers associated with accessing care, including scheduling challenges, travel, and lengthy wait times.
Expanding Access to Convenient Healthcare
Brio Rx was established with a focus on improving access to physician-led healthcare through technology. Traditional healthcare appointments can require patients to coordinate schedules, travel to medical offices, and wait weeks for available appointments. The company's telehealth model is designed to provide another option for patients who prefer to begin their healthcare journey online.
Through the Brio Rx platform, patients can complete an online intake and provide information about their health concerns and treatment goals. A licensed healthcare provider then reviews the information and determines whether treatment is appropriate. When clinically indicated, the provider may prescribe medication that can be fulfilled through a licensed U.S. pharmacy and shipped directly to the patient.
Brio Rx emphasizes that convenience does not replace clinical responsibility. Treatment decisions are made by licensed providers following an individual evaluation, with patient health and safety remaining central to the process.
A Patient-Centered Approach to Telehealth
At the center of the Brio Rx platform is a patient-centered approach designed to make healthcare easier to navigate. Rather than requiring patients to visit a physical clinic for every step of the process, the platform allows consultations and follow-up care to be conducted remotely when appropriate.
Patients can begin by completing an online health assessment. Following the evaluation, a licensed provider can discuss available treatment options and determine whether a prescription is medically appropriate. Consultations may be conducted by phone or video, depending on the circumstances and provider requirements.
The company also emphasizes transparency throughout the patient experience. Patients can review treatment information and associated costs before proceeding, while ongoing support is available to help patients understand their treatment and stay connected with their healthcare providers.
"Healthcare should be simple, accessible, and built around the patient. At Brio Rx, we're combining clinical expertise with modern technology to remove barriers to care and help people achieve better health outcomes with confidence," said Thomas Rogers of Brio Rx.
Personalized Care for Hair Loss and Men's Health
One of the primary areas served by Brio Rx is hair loss and hair restoration. Hair loss can affect both men and women and may have a significant impact on confidence and quality of life. Brio Rx provides access to physician-guided treatment options designed around each patient's individual circumstances.
The platform also provides men's health services, giving patients a convenient way to discuss personal health concerns with licensed medical providers from the privacy of their own homes.
Rather than relying on a standardized approach for every patient, Brio Rx evaluates each individual's health information before recommending treatment. This process allows providers to consider relevant medical history, current concerns, and treatment goals when developing an appropriate care plan.
More information about Brio Rx's hair loss services is available through its men's hair loss treatment program.
Supporting Patients Beyond the Initial Consultation
Brio Rx's telehealth model extends beyond a single online consultation. The company emphasizes continued clinical support throughout the treatment process, allowing patients to remain connected with their healthcare providers as they progress through their care plans.
Follow-up support can help patients better understand their treatment, address questions, and communicate relevant changes to their providers. This ongoing approach is intended to create a more connected healthcare experience rather than treating the initial prescription as the end of the patient relationship.
The company also places an emphasis on privacy and secure communication. By providing healthcare services through a digital platform, Brio Rx seeks to give patients greater flexibility while maintaining appropriate clinical and privacy standards.
Combining Medical Expertise With Technology
Technology serves as an important part of the Brio Rx healthcare model, but the company emphasizes that digital tools are intended to support licensed medical professionals rather than replace them.

From the initial online intake through provider evaluation, prescription fulfillment, and follow-up care, the platform is designed to connect different parts of the healthcare experience in a convenient digital environment.
Brio Rx works with licensed healthcare providers and licensed pharmacies in the United States to support the prescription process. Treatment is provided only when a licensed medical provider determines that it is appropriate for the individual patient.
The company also provides treatment information, safety considerations, and applicable disclaimers so patients can make informed decisions about their care. Certain treatments may involve compounded medications that are not approved by the United States Food and Drug Administration. Patients are encouraged to review the information provided by their healthcare provider before beginning treatment.
Part of the Continued Growth of Digital Healthcare
The launch of Brio Rx comes as telehealth continues to provide patients with new ways to connect with healthcare professionals. Virtual care can offer greater flexibility for people who may have difficulty fitting traditional appointments into their schedules or who prefer receiving appropriate care from home.
Brio Rx aims to contribute to this evolving healthcare landscape by combining online access with physician oversight and prescription fulfillment. The company's model is built around reducing unnecessary friction while preserving the importance of professional medical evaluation.
By bringing consultations and ongoing support into a digital environment, Brio Rx seeks to make healthcare more accessible to patients while giving them greater flexibility in how they engage with their providers.
Additional information about Brio Rx and its healthcare services is available through the Brio Rx website.
About Brio Rx
Brio Rx is a physician-led telehealth company focused on making modern healthcare more convenient, personalized, and accessible. Through its secure digital platform, Brio Rx connects patients with licensed healthcare providers for online consultations, personalized treatment plans, prescription care, and ongoing clinical support.
The company provides services focused on areas including hair loss, hair restoration, men's health, and other wellness needs. Treatments are provided following evaluation by licensed medical providers, with prescriptions fulfilled through licensed United States pharmacies when appropriate.
To learn more, visit the Brio Rx website, follow the company on Instagram, or connect with Brio Rx on LinkedIn. For inquiries and support, email [email protected].
Contact Info:
Name: Thomas Rogers
Email: Send Email
Organization: Brio Rx
Website: https://briorx.com
Release ID: 89203157
Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.
Coway is promoting three mattresses under its BEREX brand to meet diverse sleeping preferences, offering options for people with different sleeping postures and couples who prefer different levels of firmness. The company said its lineup is designed to accommodate differences in body shape and sleeping habits, as Koreans tend to get relatively little sleep, making it increasingly important for consumers to improve their sleep quality. According to a 2024 survey by the Korean Society of Sleep Research, Koreans sleep an average of six hours and 58 minutes a day, placing the country among the lowest-ranked OECD members in terms of sleep duration. With limited hours of sleep, more consumers are seeking better-quality rest, making it increasingly important for mattress makers to address their diverse needs. For people who sleep on their backs or prefer firmer support, Coway recommends the BEREX Modi Mattress, which uses individually pocketed signature springs made with high-strength steel wire from POSCO for durability and stability, along with Contour 7-Zone Foam designed to distribute body
Budding artificial intelligence (AI) researchers presented the results of their work during an internship program jointly organized by Microsoft Research and the Institute of Information & Communications Technology Planning & Evaluation (IITP), showcasing new findings in areas such as visual agentic AI, brain-inspired AI, AI-native systems and spatial intelligence. Microsoft, IITP and the Ministry of Science and ICT jointly held the 2026 Korea Day presentation event at Microsoft Korea Office in central Seoul, Tuesday, with over 100 students, mentors and officials from Microsoft Research Asia (MSRA) and IITP attending. IITP is the policy-planning and management arm of the ministry. “By embracing interdisciplinary and cross-boundary research rooted in Asia Pacific, we aim to define the new paradigm of computing and AI for the better,” Microsoft Research Accelerator Director Lee Mi-ran said. “Our collaboration with Korea is not a series of one-off events. It has been built steadily over more than 20 years … Government provides the framework, universities provide the talent and idea
Mercedes-Benz Korea is betting that a more affordable all-electric CLA sedan will revive its flagging electric vehicle (EV) business in the country, as Tesla and Chinese rivals gain ground in one of Asia’s most competitive imported-car markets. The German luxury automaker introduced the all-new electric CLA and GLC on Monday, with the entry-level CLA coupe-type sedan priced from 52.9 million won ($40,000). The pricing marks a major shift from Mercedes-Benz’s traditional premium positioning, placing its new electric sedan closer to mass-market alternatives, including Tesla’s Model Y, which starts at 49.99 million won in Korea. The Model Y was the country’s best-selling vehicle last month, largely due to its competitive pricing. The launch of the price-competitive CLA comes as Mercedes-Benz struggles to rev up sluggish EV sales. The company’s electric car lineup, previously a major source of growth, has lost momentum following the August 2024 fire involving a Mercedes-Benz EQE sedan in an underground parking garage in Incheon. Mercedes-Benz’s EV sales in Korea reached a peak of
LIG Defense & Aerospace (LIG D&A) and Doosan Enerbility have agreed to jointly develop engines for guided missiles and aircraft, combining the defense firm’s missile expertise with the power equipment maker’s turbine technology, LIG D&A said Tuesday. The two companies signed a memorandum of understanding on Monday at Doosan Tower in the Bundang area of Seongnam, Gyeonggi Province. The ceremony was attended by the head of LIG D&A’s missile systems business division, the head of Doosan Enerbility’s power service business group and other senior officials. LIG D&A, formerly known as LIG Nex1, is Korea’s leading maker of guided weapons, which are missiles and other munitions that can be steered toward a target after launch. The company changed its name in March to reflect its expansion into aerospace. Doosan Enerbility, best known for building power plant equipment, is developing next-generation aircraft propulsion technology based on expertise built up in gas turbines for electricity generation. Under the agreement, the companies will pair LIG D&A’s capabilities in developing and
HD Korea Shipbuilding & Offshore Engineering (HD KSOE) said Tuesday it has secured a 1.91 trillion-won ($1.44 billion) order from South Korean shipping company HMM to build eight liquefied natural gas (LNG) dual-fuel container ships. HD KSOE, the shipbuilding subholding company of HD Hyundai, said the vessels will be equipped with engines capable of running on both LNG and conventional marine fuels. The 13,000-twenty-foot-equivalent-unit (TEU)-class ships will measure 337 meters in length, 51 meters in width and 27.9 meters in height. Two vessels will be built at affiliate HD Hyundai Heavy Industries' shipyard in the southeastern city of Ulsan. The remaining six will be constructed at HD Hyundai Samho's shipyard in the southwestern city of Yeongam. All eight vessels are scheduled to be delivered to HMM in stages by 2029. With the latest contract, HD KSOE has secured orders worth $20.19 billion for 182 vessels so far this year, achieving 86.6 percent of its annual order target.
Innocean, the advertising affiliate of Hyundai Motor Group, said Tuesday its overseas units have won seven honors at advertising awards in the United States and the Middle East. Innocean USA received two silver awards at the 2026 Jay Chiat Awards, hosted by the American Association of Advertising Agencies. The 29-year-old competition judges anonymized case studies on how strategic thinking delivered real business results. Hyundai Motor’s “IONIQ 9 Escape Garage” won silver in the influencer and creator strategy category, while Genesis’ “A New Beginning in Luxury” took silver in automotive strategy. Both were produced with Canvas Worldwide, Innocean’s U.S. media subsidiary. In the IONIQ 9 campaign, three creator families used the electric SUV’s interior space, seating and EV features to complete escape-room missions, drawing 8.6 million views. Innocean USA’s social media team was also named in the agency social media category of marketing publication Adweek’s Team Visionary Awards. Its work included “Hyundai Jingle Road Trip,” which turned a jingle TikTok users made
Hankook Tire is extending its presence in global football as it returns for a third consecutive year as an official sponsor of the Ballon d’Or, with this year’s ceremony marking the award’s 70th anniversary and its first edition in London. Hankook Tire & Technology, part of Hankook & Company Group, said it will sponsor the 2026 Ballon d’Or ceremony, scheduled for Oct. 26 at the London Palladium Theatre. Established in 1956 by French football magazine France Football, the Ballon d’Or is widely regarded as one of the highest individual honors in football, recognizing players for their performances during the previous season. Since 2024, France Football, part of the L’Équipe Group, has organized the awards in partnership with UEFA. This year’s ceremony moves to London for the first time, commemorating seven decades since the award’s founding and paying tribute to Stanley Matthews, the England international who won the inaugural Ballon d’Or in 1956. The ceremony will also reveal the successors to last year’s winners, Aitana Bonmatí and Ousmane Dembélé. Hankook Tire said
CJ ONE is bringing its rewards program onto public transit, joining forces with mobility fintech company E-Dreams to connect travel, shopping and dining through a single membership platform for Korean and international customers. CJ OliveNetworks, which operates the lifestyle membership service, said Tuesday it had signed a memorandum of understanding with E-Dreams to expand membership benefits into mobility and payment services. The agreement was signed Monday at E-Dreams’ headquarters in central Seoul, with Yoo In-sang, CEO of CJ OliveNetworks, and Lee Jung-hwan, CEO of E-Dreams, in attendance. The first initiative will be a transportation card designed for international visitors to Korea, scheduled for release by the end of 2026. The card will combine E-Dreams’ public transportation payment functions with CJ ONE membership benefits, allowing foreign tourists to use buses and subways while earning and redeeming points at participating businesses. Distribution is planned through E-Dreams’ existing retail network, including airports and convenience stores. The partnership follows CJ
Samsung Bioepis has secured a decade-long exclusive supply deal for a rare disease treatment in Brazil, strengthening its position in Latin America’s largest pharmaceutical market while opening a new chapter in its partnership with the Brazilian government. The Korean biopharmaceutical company said Tuesday it had signed a local partnership agreement to supply SB12, a biosimilar of Soliris with the active ingredient eculizumab, to Brazil’s Ministry of Health. SB12 is used to treat rare conditions including paroxysmal nocturnal hemoglobinuria, a blood disorder, and atypical hemolytic uremic syndrome, which can damage blood cells, kidneys and other organs. Brazil’s health regulator, the National Health Surveillance Agency, known as ANVISA, approved the drug in December 2024. The Brazilian eculizumab market was worth about $170 million (250 billion won) last year, according to the company, which expects the 10-year exclusive supply agreement to provide a stable source of revenue. Under the government-led Productive Development Partnership program, Samsung Bioepis will work with Brazilia
GS Global is expanding into carbon credit trading through an equity investment in Hooxi Partners, a Korean carbon credit specialist, seeking to monetize emissions reductions from its existing eco-friendly businesses. GS Global said Tuesday that the investment would establish a strategic partnership, combining Hooxi Partners’ carbon reduction expertise with GS Global’s global network and trading capabilities. The investment comes as Korea's fourth emissions trading scheme, covering 2026-2030, takes effect. Tighter emissions caps, expanded paid allocations and stricter global carbon regulations are raising the cost of securing carbon credits and increasing exposure to price volatility. GS Global aims to turn carbon credits into a new growth engine. Founded in 2021, Hooxi Partners offers services ranging from carbon credit methodology development and emissions reduction project management to securing Korean Offset Credits (KOCs) and forward trading. The company focuses on transportation-related emissions reduction projects, particularly the transition to electric vehicles. It also oper
North Chungcheong Province said Tuesday it will hold its annual cosmetics and beauty expo in Cheongju to help Korean companies expand exports of cosmetics and other beauty products. The Cosmetics & Beauty Expo Osong Korea 2026 will run from Thursday to Saturday in Osong, a district of Cheongju, 83 kilometers south of Seoul. The event aims to connect local companies with international buyers, according to the provincial government. More than 250 companies are expected to participate in the business-to-business (B2B)-focused event, which is being held under the theme "K-Beauty Osong seeks growth along with global partners." "This year's expo, the largest edition to date, will provide local companies with opportunities to expand into overseas markets and allow visitors to experience K-beauty products," Jang Woo-sung, director general of the provincial government's bureau of biologics, food and drugs, said. The expo has been held annually in Cheongju since 2013, except in 2014. The provincial government has partnered with the Korea Trade-Investment Promotion Agency (KOTRA) to invite 200 domes
Hyundai Motor and its sister company Kia said Tuesday they will conduct test operations of Level 4 autonomous trucks as part of an ongoing effort to advance self-driving technology and pave the way for commercialization. The automakers signed a memorandum of understanding (MOU) for the project with Hyundai Motor Group affiliates Hyundai Mobis Co. and Hyundai Glovis Co., as well as autonomous driving technology startups Mars Auto and RideFlux, at the group's Namyang R&D Center in Hwaseong, southwest of Seoul. Level 4 autonomous driving allows vehicles to operate without human intervention, including in emergency situations, under specified conditions and within designated operational areas. According to the MOU, Hyundai Motor and Kia will develop and supply two Xcient trucks, including a hydrogen fuel cell model, early next year. The test program will cover approximately 500 kilometers across two routes: a 100-kilometer section combining highways and urban roads, and a 400-kilometer long-distance highway route.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.